Trade Arcus Biosciences, Inc. - RCUS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.8 |
| Open | 7.57 |
| 1-Year Change | -60.03% |
| Day's Range | 7.47 - 7.82 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 7.66 | -0.03 | -0.39% | 7.69 | 7.84 | 7.43 |
| Mar 31, 2025 | 7.80 | -0.01 | -0.13% | 7.81 | 7.94 | 7.46 |
| Mar 28, 2025 | 8.12 | -0.29 | -3.45% | 8.41 | 8.48 | 8.04 |
| Mar 27, 2025 | 8.42 | 0.26 | 3.19% | 8.16 | 8.47 | 8.06 |
| Mar 26, 2025 | 8.21 | -0.03 | -0.36% | 8.24 | 8.36 | 7.97 |
| Mar 25, 2025 | 8.35 | -0.50 | -5.65% | 8.85 | 8.96 | 8.25 |
| Mar 24, 2025 | 9.03 | 0.17 | 1.92% | 8.86 | 9.12 | 8.81 |
| Mar 21, 2025 | 8.88 | 0.07 | 0.79% | 8.81 | 9.09 | 8.74 |
| Mar 20, 2025 | 8.97 | 0.14 | 1.59% | 8.83 | 9.40 | 8.83 |
| Mar 19, 2025 | 9.04 | 0.36 | 4.15% | 8.68 | 9.06 | 8.68 |
| Mar 18, 2025 | 8.89 | -0.03 | -0.34% | 8.92 | 9.18 | 8.82 |
| Mar 17, 2025 | 9.05 | -0.07 | -0.77% | 9.12 | 9.27 | 8.92 |
| Mar 14, 2025 | 9.29 | -0.17 | -1.80% | 9.46 | 9.60 | 9.21 |
| Mar 13, 2025 | 9.47 | -0.10 | -1.04% | 9.57 | 9.79 | 9.40 |
| Mar 12, 2025 | 9.64 | -0.08 | -0.82% | 9.72 | 9.89 | 9.34 |
| Mar 11, 2025 | 9.84 | 0.63 | 6.84% | 9.21 | 9.97 | 9.14 |
| Mar 10, 2025 | 9.35 | -0.01 | -0.11% | 9.36 | 9.41 | 8.96 |
| Mar 7, 2025 | 9.53 | -0.23 | -2.36% | 9.76 | 9.93 | 9.45 |
| Mar 6, 2025 | 9.95 | 0.49 | 5.18% | 9.46 | 10.08 | 9.37 |
| Mar 5, 2025 | 9.77 | 0.24 | 2.52% | 9.53 | 9.80 | 9.36 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Arcus Biosciences, Inc. Company profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company''s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.| Industry: | Biotechnology & Medical Research (NEC) |
3928 Point Eden Way
HAYWARD
CALIFORNIA 94545-3719
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com